Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
46 participants
INTERVENTIONAL
2019-04-01
2023-05-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Emotion Study -- A Neurofeedback Approach
NCT02194907
Magnetic Resonance Imaging of the Brain in Emotional Processing
NCT00061204
Brain Self-regulation for Parkinson's
NCT05627895
Targeting Large-scale Networks in Depression With Real-time fMRI (Functional Magnetic Resonance Imaging) Neurofeedback
NCT05934604
Stimulation-Induced Changes in Fronto-Limbic Network
NCT05854160
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Based on these theoretical considerations as well as the previous study's data, the proposed research will apply well-tested emotion processing and attention paradigms to address the pivotal question of whether brain activity can be modulated in healthy aging and PD (in the substudy) via contingent rt-fMRI neurofeedback and whether this neuroregulatory modulation increases emotion processing and cognitive performance.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Healthy Younger Group
Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
Anterior cingulate cortex activation
Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.
The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing.
Healthy Older Group
Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
Anterior cingulate cortex activation
Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.
The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing.
Parkinson Disease Group
Participants will receive rt-fMRI training to increase anterior cingulate cortex activation.
Anterior cingulate cortex activation
Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.
The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing.
Control Group
Participants will receive rt-fMRI training to increase primary auditory cortex activation.
Primary auditory cortex activation
Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as "control/placebo" condition in the current design (placebo comparator).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anterior cingulate cortex activation
Functional Magnetic Resonance Imaging Participants in the experimental group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior cingulate cortex.
The anterior cingulate cortex is a brain region that is known to be involved in emotion processing. Activation of this region is expected to improve emotion processing.
Primary auditory cortex activation
Functional Magnetic Resonance Imaging Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in primary auditory cortex. The primary auditory cortex is a brain region that is NOT specifically involved in emotion processing. Activation of this region is NOT expected to improve emotion processing; and thus activation of this brain region serves as "control/placebo" condition in the current design (placebo comparator).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* native English speaker
* at least 8th grade education
* generally physically and neurologically healthy as determined by the Health Demographics Screener
* eligible for MRI as determined by the MRI Eligibility Interview (including not being pregnant)
* scores within normal limits on a cognitive screener (MoCA)
* no indication of serious psychiatric disturbance including major depression (based on Mental Health Screener)
* willing and able to give informed consent
* age 55-100 years of age
* native English speaker
* at least 8th grade education
* generally physically and neurologically healthy as determined by the Health Demographics Screener
* eligible for MRI as determined by the MRI Eligibility Interview
* no indication of dementia based on score of 30 or above on the Telephone Interview for Cognitive Status and nonimpaired score on the Montreal Cognitive Assessment (MoCA -- score of 22 and above)
* no indication of serious psychiatric disturbance including current major depression (based on Mental Health Screener)
* willing and able to give informed consent
* must meet criteria for diagnosis of idiopathic Parkinson disease according the UK Brain Bank by a movement trained neurologist.
* age 55-100 years of age
* native English speaker
* at least 8th grade education
* generally physically and neurologically healthy other than Parkinson disease
* eligible for MRI as determined by the MRI Eligibility Interview
* no indication of dementia based on cognitive screening measures (TICS -- score of 30 or above, and MoCa -- score of 22 and above)
* no indication of serious psychiatric disturbance including current major depression
* willing and able to give informed consent
* age 55-100 years of age
* native English speaker
* at least 8th grade education
* generally physically and neurologically healthy as determined by the Health Demographics Screener
* eligible for MRI as determined by the MRI Eligibility Interview
* no indication of dementia based on score of 30 or above on the Telephone Interview for Cognitive Status and nonimpaired score on the Montreal Cognitive Assessment (MoCA -- score of 22 and above)
* no indication of serious psychiatric disturbance including current major depression (based on Mental Health Screener)
* willing and able to give informed consent
* community-dwelling with subjective report of cognitive complaints with scores \>16 on the Cognitive Change Index (CCI-20)
* no evidence of dementia or mild cognitive impairment based on cognitive screening using the MoCA; scores must fall within normal limits for age, education, and sex
* no psychometric evidence of neuropsychological impairment on a modified Neuropsychological Battery from the NACC Unified Data Set, version 3
* score of 0 on the Global Clinic Dementia Rating (CDR) scale
* normal functional behavior in terms of daily activities, based on the Functional Activities Scale (FAQ)
* availability of an informant (over the phone) who can provide information about the participant's complaints using the informant version of the CCI-20, and corroborate normal activities of daily living on the FAQ and the CDR scale.
Exclusion Criteria
* Claustrophobia
* Large pieces of metal in the body, particularly in the face and neck.
* Piercings or metal implants that cannot be removed from the body
* Surgery on the brain or any prior serious brain damage or disease
* Dementia or severe cognitive disorders
* use of antipsychotics, sedatives, or other medications with significant anticholinergic properties (due to potential influence on memory)
* use of prescribed 'memory enhancing' medications such as Aricept or Namenda.
18 Years
100 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Aging (NIA)
NIH
Florida Department of Health
OTHER_GOV
National Center for Advancing Translational Sciences (NCATS)
NIH
University of Florida
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Natalie Ebner, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Florida, Department of Psychology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Florida
Gainesville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.